Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Verucerfont (NBI77860) is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) .
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 62.00 | |
5 mg | In stock | $ 183.00 | |
10 mg | In stock | $ 315.00 | |
25 mg | In stock | $ 529.00 | |
50 mg | In stock | $ 768.00 | |
100 mg | In stock | $ 1,080.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 198.00 |
Description | Verucerfont (NBI77860) is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) . |
Targets&IC50 | CRF1:~6.1nM, CRF2:1000 nM, CRF BP:>1000 nM |
In vivo | Verucerfont potently blocked the HPA axis response to the dexamethasone-CRF test, but left alcohol craving unaffected.?Right amygdala responses to negative affective stimuli were significantly attenuated by verucerfont, but responses to alcohol-associated stimuli were increased in some brain regions, including left insula[1]. |
Synonyms | NBI77860, GSK561679 |
Molecular Weight | 406.48 |
Formula | C22H26N6O2 |
CAS No. | 885220-61-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 86.7 mg/mL (213.29 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Verucerfont 885220-61-1 GPCR/G Protein CRFR NBI77860 Corticotropin-releasing Factor Receptor Inhibitor NBI-77860 GSK 561679 GSK-561679 NBI 77860 GSK561679 inhibit inhibitor